nexobrid — Regulatory decision
Q4 2026
EMA-requested modifications are being implemented following the pre-audit of the expanded NexoBrid manufacturing facility, with completion expected in the fourth quarter of 2026.Source filing
MDWD biotech catalysts & pipeline
MEDIWOUND LTD · Data as of 2026-09-08
Upcoming catalysts
escharex — Interim data
Q1 2027
The EscharEx Phase III VALUE trial is advancing across the U.S., Europe, and Israel, with the interim sample size reassessment and completion of enrollment expected by the end of the first quarter of 2027.Source filing
NexoBrid ® — Regulatory decision
2027
Vericel reported broad utilization across more than 60 burn centers and plans to pursue a permanent CPT code, which would become effective in 2027.Source filing